the Web site devoted to the study of the glucagon-like peptides
This Web site is maintained by Dr. Daniel J. Drucker, Mount Sinai Hospital Lunenfeld-Tanenbaum Research Institute University of Toronto
The discovery of GLP-1-the key events
Welcome to Glucagon.com
- HOME AND SEARCH
- COVID-19, SARS-CoV-2 and Diabetes
- GLUCAGON
-
GLP-1
- GLP-1
- GLP-1 and the alpha cell
- GLP-1 therapy adverse events
- GLP-1 and the b-cell
- GLP-1, b-cell proliferation and differentiation and apoptosis
- GLP-1 and islet transplantation
- GLP-1 and insulin sensitivity
- GLP-1 and gastric emptying
- GLP-1 and the cardiovascular system
- GLP-1 action in the CNS
- GLP-1 and the portal signal
- GLP-1 and food intake
- GLP-1 actions independent of glucose homeostasis
- GLP-1 receptor
- GLP-1 Receptor Desensitization
- GLP-1 actions and a second GLP-1 receptor
- GLP-1R-/- mice
- GLP-1 synthesis and secretion, and degradation
- GLP-1 and hypoglycemia
- GLP-1(9-36)amide
- GLP-1 action in human subjects
- GLP-1 ACTION IN NON-DIABETIC SUBJECTS
- GLP-1 ACTION IN TYPE 2 DIABETES
- GLP-1R agonists and human diabetes
- Liraglutide
- Exendin-4: Human Data
- EXENATIDE ONCE WEEKLY
- GLP-1 analogues and human diabetes
- GLP-1 actions and a second GLP-1 receptor
- albiglutide & dulaglutide
- GLP-1 targets
- Alternative GLP-1 delivery systems
- glp-1, inflammation & immune function
- GLP-2
- Drucker Lab
- DPP-4
- GIP
- Glicentin
- Glucagon Gene
- Gut endocrine cells
- Islet α-cells
- Links
- Oxyntomodulin
- Receptors
- Research Reagents
- The Incretin Effect
Copyright © 2008 Glucagon.com
Last Updated: October 2, 2023
Last Updated: October 2, 2023